Burden of Shigella among children with diarrhea in the Americas: A systematic review and meta-analysis
Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Advancements in Understanding and Combatting Shigella Infections
Published on: February 9, 2024
Maya Lubeck-Schricker1, Andrea C Rivas-Nieto1, Jennifer Rosauer1
1Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.
Insights
Shigella bacteria significantly contribute to childhood diarrhea in the Americas. Standardized surveillance is crucial for developing effective Shigella vaccines tailored to regional needs.
Area of Science:
- Infectious Diseases
- Public Health
- Vaccinology
Background:
- Shigella is a major global cause of diarrheal disease, with a significant burden observed in the Americas.
- Pediatric Shigella vaccines are in clinical development, necessitating an understanding of regional disease burden for policymakers.
Purpose of the Study:
- To systematically review and meta-analyze the burden of Shigella diarrhea in children under 72 months in the Americas (excluding U.S., Canada, Greenland).
- To inform potential Shigella vaccine implementation strategies in the region.
Main Methods:
- Systematic review and random effects meta-analyses of published and pre-print articles from 2000-2024.
- Searched six databases for studies on Shigella prevalence, incidence, and attributable fraction in children under 72 months.
- Included 34 studies from 14 countries, analyzing data based on detection methods (culture, PCR/qPCR) and age groups.
Main Results:
- Pooled prevalence of Shigella among diarrhea cases was 3.1% (culture) and 16.5% (PCR/qPCR).
- Prevalence varied by age, with higher rates in children ≥12 months (4.6%) compared to <12 months (1.0%) using culture methods.
- Significant heterogeneity was observed across studies, with limited geographic representation and variable age-specific data.
Conclusions:
- Shigella is an important cause of diarrhea in the Americas, though data reporting is inconsistent.
- Gaps in data include limited geographic coverage and variable age-specific estimates.
- Standardized Shigella surveillance in the Americas is recommended to support vaccine development and introduction decisions.
Introduction:
Shigella is a leading cause of diarrhea worldwide. While the burden of Shigella has been shown to be highest in Africa and Asia, recent studies have also shown considerable burden in the Americas. With several pediatric Shigella vaccines in clinical development, policymakers in the region will eventually consider whether a Shigella vaccine is appropriate for their setting.
Methods:
We conducted a systematic review and meta-analyses to summarize the burden (characterized by prevalence, incidence, and attributable fraction estimates) of Shigella diarrhea among children under 72 months in the Americas, excluding the U.S., Canada, and Greenland. We searched published and pre-print articles available in six databases from January 1, 2000 through July 18, 2024. Random effects meta-analyses were conducted for subgroups of interest when relevant data from at least two studies were present.
Results:
This review included 34 studies conducted across 14 countries in the region. Prevalence was most frequently reported, followed by incidence, then attributable fraction. Across all prevalence studies that used a culture detection method (n = 23), the pooled prevalence of Shigella among diarrhea cases was 3.1% (95% CI: 1.6- 5.8). The pooled prevalence among 7 studies that used PCR/qPCR detection methods was 16.5% (95% CI: 11.1-24.0). Among culture-based results, the pooled prevalence estimate for children <12 months was 1.0% (95% CI: 0.1 - 7.7) compared to 4.6% (95% CI: 1.2 - 15.4) for children ≥12 months.
Conclusion:
Despite varying reporting practices, we found Shigella to be an important contributor to diarrhea in many settings in the Americas with substantial heterogeneity. Limited geographic representation and variable reporting of age group specific estimates were the major gaps in data. Investment in Shigella surveillance in the Americas using a standardized methodology can contribute to accelerating Shigella vaccine development in consideration of regional preferences and optimal age of introduction.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Sexually Transmitted Infections
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Fungal Phylum Microsporidia

